S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
NCT00003127
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic, recurrent, or refractory endometrial cancer.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
06/13/2012
Locations: Veterans Affairs Medical Center - Denver, Denver, Colorado +1 locations
Conditions: Endometrial Cancer
Register for Updates
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine
NCT00390676
Completed
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2010
Locations: Rocky Mountain Cancer Centers, Denver, Colorado
Conditions: Neoplasms
Register for Updates
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
NCT00034541
Completed
The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Denver, Colorado
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
NCT00087802
Completed
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2009
Locations: Rocky Mountain Cancer Centers, Denver, Colorado
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates